(UroToday.com) There have been significant changes in the landscape of treatment of metastatic hormone-sensitive prostate cancer (mHSPC) over the last five years, beginning with the publication of the CHAARTED trial and STAMPEDE Arm C demonstrating improved overall survival for patients receiving docetaxel in addition to androgen deprivation therapy. Subsequently, in 2017, the LATITUDE trial and STAMPEDE Arm G demonstrated improved overall survival for men who received abiraterone acetate in addition to androgen deprivation therapy (ADT), in comparison to ADT alone. Since that time, apalutamide and enzalutamide have joined the list of approved and guideline-recommended agents in this disease space.